Biosimilars and Pharma Innovations

Consequences of Brexit on Biosimilars

In biosimilar replacement resulted in significant reductions in aggregate provider risk, implying that this possible intervention for providers to limit risk in VBP models for cancer care should be continued. Oncology biosimilars may play an important role in reducing provider risk in VBP models. The impact of bio similar substitution on provider risk is unknown, as previous research has primarily focused on the financial impact of generic adoption. Researchers modelled the quantitative technique of Medicare's OCM to quantify the impact of substitution on financial risk to providers in VBP models. Bevacizumab, rituximab, trastuzumab, epoetin alfa, filgrastim, and pegfilgrastim biosimilars were evaluated. Brexit- Pros and Cons to European pharma market

• Post Brexit changes in biosimilars regulation in UK
• Fate of biosimilars clinical trials in UK
• Research funding from European organizations to UK based research laboratories